Clinical Trial Update: Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy [Phase 2]

View source ↗

Summary

A phase 2 trial of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Kynamro (mipomersen)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Hypercholesterolemia, Familial | Phase 2 | Status: COMPLETED